ZIOP Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 Jan 2022 @ 06:00):

Stats
Tagesvolumen	2.13M
Durchschnittsvolumen	2.36M
Marktkapitalisierung	208.12M
EPS	$0 ( 2022-02-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.07
ATR14	$0.104 (12.01%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-22	De Groot Eleanor	Sell	20 132	Common Stock
2021-03-04	Thistle Mary	Buy	150 000	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	37 500	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	5 000	Common Stock
2021-03-04	Buchi J Kevin	Buy	31 250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 95 transactions
Buy: 4 516 054 \| Sell: 1 683 458

Volumen Korrelation

Lang: 0.25 (neutral)

Kurz: 0.41 (neutral)

Signal:(38.327) Neutral

ZIOPHARM Oncology Inc Korrelation

10 Am meisten positiv korreliert
JAGX	0.926
MICS	0.922
FCBC	0.92
ONEM	0.917
BWB	0.915
PSHG	0.914
CVBF	0.91
AROW	0.91
CYRN	0.908
BMRC	0.905

10 Am meisten negativ korreliert
ITAQU	-0.963
MCAA	-0.954
OPRA	-0.945
RCEL	-0.941
COCO	-0.939
BRLI	-0.938
ARYD	-0.937
APTM	-0.935
SLAM	-0.935
TZPS	-0.934

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

ZIOPHARM Oncology Inc Korrelation - Währung/Rohstoff

0.12
( neutral )

-0.71
( moderate negative )

0.00
( neutral )

-0.23
( neutral )

0.83
( strong )

-0.21
( neutral )

ZIOPHARM Oncology Inc Finanzdaten

Annual	2020
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.380

FY	2020
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.380

FY	2019
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.700

FY	2018
Umsatz:	$146 000
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

ZIOPHARM Oncology Inc

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.